Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Publication | Open Access

DOI Full Paper Access

712

Citations

References

2022

Year

Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu, Do‐Youn Oh, Sang Cheul Oh, Hyun Cheol Chung, Keun-Wook Lee, Takeshi Omori, Kohei Shitara, Shinichi Sakuramoto,

The Lancet Oncology

Abstract

References